Selective Estrogen Receptor Degraders (SERDs) in Hormone Receptor Positive Breast Cancer
One of the main themes at this year’s San Antonio Breast Cancer Symposium was SERDs (selective estrogen receptor degraders) in both early stage and metastatic breast cancer. In this video, I talk about what they are, how they work and how we are using them- and ongoing clinical trials. #breastcancer #serd #oncologist
▶︎
Hormone Replacement After Breast Cancer? What Every Woman Deserves to Know
▶︎
This Isn't Experimental: Breast Cancer Just Got 3 NEW DRUGS | Cancer Drug Designer
▶︎
Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer
▶︎
Multi-Cancer Early Detection Blood Tests | Oncologists Discuss the NHS-Galleri Trial
▶︎
Breaking Down Aromatase Inhibitors: What Doctors Don't Say
▶︎
OB-GYN x Oncologist Session 2: ASCO Updates on GLP-1s in Breast Cancer, SERDs, Pregnancy After Brea
▶︎
Hormone Receptors in Breast Cancer: ER, PR, and HR Explained
▶︎
Anastrozole Mnemonic for USMLE
▶︎
The Vitamin–Liver Cancer Link I Didn’t Expect
▶︎
How Late is TOO Late to Start HRT for Women? New Research Study REVEALED
▶︎
17 Principles of Targeted Therapy
▶︎
25 Brutal Truths a Breast Surgeon Learned about Breast Cancer
▶︎
What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+
▶︎
Topical Estrogen on Your Face: What a Dermatologist Actually Thinks
▶︎
The FDA Rejected This Breast Cancer Drug. Here's Why.
▶︎
When Tamoxifen and AI's Become Unbearable
▶︎
40 Things I’ve Learned as a 5-Year Breast Cancer Survivor
▶︎
New Data on GnRH Agonists for Ovarian Function Suppression: Monthly vs Every 3 Months?
▶︎
Hormones After Breast Cancer, Dr. Corrine Menn, Dr. Kelly Casperson
▶︎